Elanix Biotechnologies AG

ISIN: DE000A0WMJQ4 | Ticker: ELN | LEI: 391200SYNFFL0NPAJK90

Sector: Health Care – Sub-Industry: Biotechnology

Country: Germany

About Elanix Biotechnologies AG

Company Description

Elanix Biotechnologies is a tissue regeneration company. We develop and commercialize products for acute wound care, dermatological and gynecological applications, as well as providing cell technology services.

The company was founded in 2012 as a spin-off from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks containing vast quantities of cells.
The Company is headquartered in Epalinges, Switzerland with offices in Hamburg and listed on the Frankfurt stock exchange under the symbol ELN.

Year founded

1994

Served area

Europe

Headquarters

c/o Frankfurt Hanauer Landstraße BC GmbH / Hanauer Landstraße 291 B, 60314 Frankfurt – Germany

Filings & Publications

Insider Trades

Capital markets information

ISIN

DE000A0WMJQ4

LEI

391200SYNFFL0NPAJK90

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Designated Sponsor

mwb fairtrade Wertpapierhandelbank AG

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations department

First name*

Last name*

Your email*

Your phone number

Your company

Your message

I agree to the terms of the privacy policy.*

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.